AbbVie (ABBV) Wins "Nobel Prize" in Medicine

     The biopharmaceutical company, AbbVie (ABBV) has won the Prix Galien 2015 award for best pharmaceutical agent.  Specifically, the award recognizes the blood cancer treatment, IMBRUVICA, which AbbVie (ABBV) recently acquired in a multi-billion dollar deal.

The Prix Galien is very prestigious, as it is considered the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.  This is not the first time that AbbVie has won it.  Back in 1999, before the pharmaceutical branch of Abbott Labs (ABT) broke off to form AbbVie (ABBV) in 2013, the business won the Prix Galien for its drug Norvir.  Then, in 2007, the Prix Galien was awarded once again in honor of the blockbuster medicine, Humira.

Considering that AbbVie (ABBV) stock went up more than 10% yesterday, when it was a down day for all three leading indexes, the honor of a Prix Galien does not come without fortune as well.

Paul Wharton
Special thanks to Eli Lilly & Co. (LLY)